Is ivonib useful for flt3 mutations?

Avosidenib is not indicated for the treatment ofFLT3 mutations. Ivonib is China's first approved potent oral targeted inhibitor for isocitrate dehydrogenase -1 (IDH1) mutated cancer. It is mainly used to treat relapsed or refractory acute myeloid leukemia (R/R) in adults carrying IDH1 susceptible mutations. AML) patients, rather than FLT3 mutations.

Avosidenib has been approved by the USFDA for three indications, all of which are targeting patients with IDH1 mutations, including multiple Refractory or refractory acute myeloid leukemia, newly diagnosed acute myeloid leukemia with susceptible IDH1 mutations (specific patient populations), and patients with previously treated locally advanced or metastatic cholangiocarcinoma. These indications are based on the presence of IDH1 mutations, not FLT3 mutations.

Avosidenib is essentially an allosteric inhibitor of IDH1. It reduces the production of carcinogenic metabolites in the body by inhibiting the mutated IDH1 enzyme, thereby inhibiting the growth and development of tumors. This mechanism is independent of treatment of FLT3 mutations.

FLT3mutations are another type of gene mutation that occur primarily in acute myeloid leukemia (AML). For the treatment of FLT3 mutations, other drugs are currently available, such as midostaurin and giritinib. These drugs are designed to treat FLT3 mutation-positive acute myeloid leukemia and have different therapeutic targets than ivonib.

ForFLT3Patients with mutations should be treated with drugs that specifically target this mutation. Therefore, it is crucial to obtain accurate genetic testing and consult with a medical professional before taking any medication to ensure that patients receive the treatment that is best for them.